Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion by Turner, MD et al.
Biosci. Rep. (2012) / 32 / 105–112 (Printed in Great Britain) / doi 10.1042/BSR20110089
Tumour necrosis factor receptor trafficking
dysfunction opens the TRAPS door to
pro-inflammatory cytokine secretion
Mark D. TURNER*1, Anupama CHAUDHRY* and Belinda NEDJAI†
*Centre for Diabetes, The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London,
Whitechapel, London E1 2AT, UK., and †Leukocyte Biology Section, National Heart and Lung Institute, Imperial College, South Kensington,
London SW7 2AZ, U.K.




Synopsis
Cytokines are secreted from macrophages and other cells of the immune system in response to pathogens. Addi-
tionally, in autoinflammatory diseases cytokine secretion occurs in the absence of pathogenic stimuli. In the case
of TRAPS [TNFR (tumour necrosis factor receptor)-associated periodic syndrome], inflammatory episodes result from
mutations in the TNFRSF1A gene that encodes TNFR1. This work remains controversial, however, with at least three
distinct separate mechanisms of receptor dysfunction having been proposed. Central to these hypotheses are the
NF-κB (nuclear factor κB) and MAPK (mitogen-activated protein kinase) families of transcriptional activators that
are able to up-regulate expression of a number of genes, including pro-inflammatory cytokines. The present review
examines each proposed mechanism of TNFR1 dysfunction, and addresses how these processes might ultimately
impact upon cytokine secretion and disease pathophysiology.
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INTRODUCTION
TRAPS {TNFR [TNF (tumour necrosis factor) receptor]-
associated periodic syndrome} is an autosomal dominant autoin-
flammatory disease linked to chromosome 12p13 [1,2], and more
specifically with mutations within the TNFRSF1A gene encoding
TNFR1. Clinically, TRAPS is characterized by recurrent attacks
of fever, abdominal pain, migratory rash, myalgia and periorbital
oedema. Attacks are typically several days to several weeks in
duration and often start in early childhood [3]. Critically, TRAPS
patients are also susceptible to the development of potentially
fatal secondary amyloidosis.
At present, 86 mutations (109 sequence variants) of
the TNFRSF1A gene have been reported to lead to
the development of TRAPS (INFEVERS TRAPS database
http://fmf.igh.cnrs.fr/infevers). Of these, 78 are single nucleotide
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missense mutations occurring within exons 2, 3, 4 and 6; the
exceptions are deletion (D42) in exon 3, and a splicing muta-
tion (c.472 + 1G→A) in intron 4. Thirty of the identified mis-
sense mutations affect extracellular cysteine residues (12 indi-
vidual cysteine residues affected, some with multiple mutations
per residue), with the majority of the mutations (91 %) being
located within CRDs (cysteine-rich domains) 1 and 2, with two
mutations (C98Y and F112I) described in CRD3, none yet in
CRD4, and I170N being the only mutation in close proximity
to the transmembrane region (exon 6) that was described in a
German family [4]. This novel mutation was, however, shown to
cause defective receptor shedding, and is associated with reduced
levels of sTNFR1 (soluble TNFR1).
Our understanding of TRAPS disease pathophysiology has
been greatly aided by studies investigating intracellular transport
of TNFR1. Although TNFR1 is found at the cell surface follow-
ing pro-inflammatory stimuli, in the absence of any such stimulus
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Figure 1 Modes of TNFR1 trafficking dysfunction associated with TRAPS
(A) Normal transport of TNFR1 and (B) intracellular trafficking defects associated with TRAPS. TNFR1 is transported along
the biosynthetic pathway through the ER to the Golgi storage pool, where the majority of the receptor is retained in cells
of the immune system. TRAPS is thought to occur as a result of a number of possible mechanisms, namely defective
TNFR1 oligomerization and ER misfolding-associated stress pathways, failed Golgi retention, impaired TNFR1 proteolytic
cleavage and receptor shedding or ligand-independent NF-κB activation.
it is instead primarily localized within Golgi storage pools [5–8].
A small fraction of TNFR1 is, however, normally trafficked to
the cell surface. When circulating TNF levels become elevated,
cell surface TNFR1 binds TNF, and the ligand–receptor com-
plex subsequently triggers either cell survival/inflammation or
apoptotic cell death pathways [9], with the cellular fate being de-
termined through a complex balance of molecular switches and
feedback mechanisms [10–14]. Crucially these cell signalling
pathways are regulated by intracellular trafficking events, and
subsequent TNFR1 compartmentalization [15,16]. Importantly,
it is also becoming increasingly clear that a large number of dif-
ferent mutations in TNFRSF1A result in receptor mislocalization
and/or ligand-independent activation. However, a consequence
of most TRAPS mutations is the activation of the transcription
factor, NF-κB (nuclear factor κB), although this is not always
the case [17]. At least three distinct and separate mechanisms of
receptor dysfunction have now been proposed (Figure 1). These
hypotheses form the basis for this mini-review.
SHEDDING HYPOTHESIS
TNFR1 is a member of the wider TNF receptor superfamily of
30 receptors and 19 associated ligands [18,19]. Although un-
der resting conditions the majority of TNFR1 is stored within
Golgi storage pools [5–8], a fraction of the global intracellular
pool of TNFR1 is instead transported to the cell surface where it
is localized within cholesterol- and sphingolipid-rich low dens-
ity membrane lipid raft microdomains [20]. Here it undergoes
metalloprotease-mediated cleavage in the receptors extracellular
domain by the transmembrane glycoprotein, ADAM17 (a dis-
integrin and metalloproteinase 17) [21], also known as TACE
(TNFα-converting enzyme). This then releases sTNFR1 into the
bloodstream where it binds circulating free TNF and attenuates
inflammation [22,23].
TRAPS disease pathophysiology was initially thought to be
the result of unopposed action of TNF due to the reduced levels
of sTNFR1 which normally acts as a physiological buffer. It was
reported that patients with the C33Y, T50M, C52F and C88R
mutations demonstrated significantly lower levels of sTNFR1
between attacks and disproportionately low levels during attacks
when compared with appropriate controls [24]. This led to the
development of the ‘shedding hypothesis’, where there is little
or no physiological cleavage of TNFR1 by metalloproteases.
Generation of a knock-in mouse with a non-sheddable form of
TNFR1 gave further support to this hypothesis, since these mice
showed increased TNF signalling and increased susceptibility to
and increased severity of induced arthritis [25].
The likely cause of defective shedding is altered conformation
in the extracellular domain of TNFR1. This can occur as a con-
sequence of cysteine missense mutations which result in unpaired
cysteine residues within the extracellular CRDs of TNFR1. In ad-
dition there are a number of non-cysteine mutations that have also
been found to cause shedding defects. Notably, T50M disrupts
a highly conserved threonine residue that is associated with an
intrachain hydrogen bond. Other non-cysteine mutations have
also been predicted to disrupt the receptors secondary structure,
thereby altering protein folding and/or TNF-binding character-
istics. Alternatively, reduced sTNFR1 might instead be a con-
sequence of a lower concentration of cell surface TNFR1. Were
this to be the case, the reduced cell surface TNF-binding capacity
might also result in a failure to activate ADAM17/TACE and to
induce downstream signalling cascades.
It is important to note that defective TNFR1 shedding is
not universal in TRAPS [3], and some patients display lower
levels of sTNFR1 during attacks compared with disease-matched
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controls, but not necessarily lower levels at baseline. In addition,
it is important to recognize that as well as ADAM17/TACE-
mediated sheddase generation of sTNFR1, full-length sTNFR1
can also be constitutively released into the bloodstream via
exosome-like vesicles, via a mechanism that is independent of re-
ceptor cleavage [26]. Therefore, while a shedding defect remains
the most likely cause of inflammation for patients carrying a num-
ber of TRAPS mutations, other mutations have been found not to
result in defective shedding, and must therefore have a different
underlying disease mechanism. This has led to the development
of additional hypotheses.
LIGAND-INDEPENDENT SIGNALLING
HYPOTHESIS
The conformational changes induced by TNF when initiating
TNFR1 signal transduction cascades have been the subject of
much debate. It was originally proposed that TNF homotrimers
induce signalling by aggregation of TNFRs, although subsequent
models proposed a minimal unit of receptor activation involving
preformed receptor dimers on the cell surface which are allos-
terically modified by ligand binding [27]. This led to the devel-
opment of the PLAD (preligand assembly domain) hypothesis,
whereby the extracellular domains of both TNFR1, as well as
TNFR6 (also known as Fas), associate in the absence of their
ligands, namely TNF or FasL respectively [28–30]. Ligand bind-
ing then stabilizes the interaction between the receptor subunits,
allowing the ligand–receptor complex to trigger a cascade of
intracellular processes with diverse, and sometimes apparently
contradictory, effects.
TNF-independent NF-κB activation is becoming increasingly
implicated in TRAPS. Yousaf et al. [30] used a doxycycline-
inducible expression system to analyse the relationship between
wild-type receptors and the T50K variant of TNFR1. Interest-
ingly, the authors found that modest up-regulation of the mutant
receptor down-regulated cell surface expression of wild-type
TNFR1 and vice versa. However, when the balance was tipped to-
wards the mutant TNFRSF1A an increase in p65 NF-κB subunit
activity was documented that was independent of TNF stimula-
tion. By contrast, when wild-type expression was elevated, there
was no increase in p65 in the absence of TNF stimulation. Cell
surface cross-linking experiments also showed that T50K recept-
ors are capable of oligomerizing with both T50K and wild-type
receptors independent of TNF stimulation [30]. This work is also
consistent with the observation that the T50M variant results in
cell-surface expression of mutant receptor with much reduced
TNF-binding capacity relative to wild-type receptor [31]. Taken
together these findings suggest that, at least in some TRAPS
mutations, TNFR1 signalling from the cell surface could be as-
sociated with an indirect route for NF-κB activation that does not
involve TNF stimulation.
In addition to activation of NF-κB, TNF-mediated inflam-
mation/cell survival can also result from additional pathways.
MAPK (mitogen-activated protein kinase) signal transduction
pathways have been implicated in multiple physiological pro-
cesses including growth, differentiation, survival and cell death
[32–34]. In humans, three groups of MAPK have been iden-
tified: the ERK (extracellular signal-regulated protein kinases),
the JNK (c-Jun N-terminal kinase) and the p38 MAPK [35–37].
The p38 MAPK pathway plays an important role in cellular re-
sponse to inflammatory stimuli and environmental stresses, and
has recently been linked to the pathophysiology of several dis-
eases including rheumatoid arthritis [38] and TRAPS [39]. A
recent study reported that heterozygous T50M and C33Y muta-
tions in macrophage TNFR1 led to enhanced activation of JNK
and p38 MAPK, but that heterozygous mutations, and even more
so homozygous mutations, diminished TNF-induced IL-6 (in-
terleukin 6) production relative to controls [39]. Furthermore,
LPS (lipopolysaccharide)-induced MAPK activation was found
to be independent of TNF, as blockade with TNFR2-Fc failed
to inhibit activation. Together these findings led the authors to
speculate that TRAPS abnormalities might therefore result from
intracellular ligand-independent TNFR1 signalling. Alternatively
TRAPS-driven MAPK activation might instead be induced indir-
ectly through other mediators, including ROS (reactive oxygen
species) [40], which can sustain MAPK signalling through inac-
tivation of MAPK phosphatases [41]. Indeed, ROS were found to
be elevated in immune cells isolated from TRAPS patients, with
altered mitochondrial function being shown to be responsible for
the enhanced oxidative capacity and pro-inflammatory cytokine
production [40]. It should also be noted that in TRAPS mutations
that generate inactive TNFR1, TNF would signal solely through
TNFR2. Under these circumstances there would then be an in-
ability of cells to induce apoptosis via death domain activation
pathways, potentially explaining the apoptosis defect found in
many cells from TRAPS patients.
INTRACELLULAR TNFR1 TRAFFICKING
DEFECTS ASSOCIATED WITH TRAPS
Molecular modelling of TNFR1 mutants predicts that TRAPS-
associated mutations in TNFR1 might profoundly disrupt
receptor trafficking [42]. Consistent with this prediction, a
number of TNFR1 mutations have been reported to result
in intracellular retention of mutant receptors within the ER
(endoplasmic reticulum) [43,44], most likely due to abnormal
oligomerization of mutant receptors through non-physiological
disulfide bonds. It was thought that the intracellular increase in
misfolded mutant TNFR1 in the ER might induce inflammation
through the UPR (unfolded protein response), which in certain
instances can induce production of pro-inflammatory cytokines
[45]. Simon et al. [39] recently challenged this hypothesis,
as they observed no spontaneous increase in the expression
of classical ER stress-inducible genes in mice possessing the
C33Y or T50M mutation in TNFRSF1A. It should be noted,
however, that this evidence is not conclusive, as alternative UPR
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pathways also exist that were not investigated. Interestingly,
Zhang et al. [45] delineated a molecular mechanism for
activation of an ER-localized transcription factor, CREBH
(cAMP-responsive-element-binding protein H), and revealed
an unprecedented link by which the ER can initiate acute
inflammatory response. Importantly CREBH does not contribute
to the classical UPR induction, but is instead required for APR
(acute phase response), regulating transcription of the CRP (C-
reactive protein) and SAP (serum amyloid P) genes, CREBH and
ATF6 (activating transcription factor 6) binding to a conserved
promoter element [45]. CREBH and ATF6 thereby interact and
synergistically regulate transcription of target genes in hepato-
cytes following ER stress. Pro-inflammatory cytokines induce
cleavage of CREBH and activate both the APR and UPR in the
liver in vivo, raising an intriguing notion that many physiological
and pathological processes that induce ER stress, such as gene
mutations that disturb protein folding as hypothesized in TRAPS,
might induce an inflammatory response through CREBH cleav-
age, activating transcription of the APR genes encoding SAP and
CRP.
While ER misfolding of TNFR1 clearly induces an inflam-
matory response, a cautionary note must be sounded with the
ER misfolding hypothesis however, as this model is largely re-
liant upon data initially generated in transfected cell lines and
‘knock-in’ mice, rather than physiologically relevant immune
cells taken from actual TRAPS patients. As vector-driven high
protein overexpression levels have sometimes been found to trig-
ger ER overload, and thereby result in the artefactual activation
of ER stress-signalling pathways, care must be taken when in-
terpreting these data. Indeed, in contrast to other studies where
cysteine and threonine mutations in TNFR1 have been linked
to failure of mutant TNFRs to elicit intracellular apoptotic sig-
nalling cascades in isolated neutrophils challenged with TNF and
cycloheximide [46], or in PBMCs (peripheral blood mononuc-
lear cells) challenged with infliximab [47], the mutants generated
by Lobito et al. [43] failed to function as inhibitors of apoptosis.
This would appear to bring into question the use of these par-
ticular vector constructs as a genuine reflection of the disease
state. Therefore the misfolding hypothesis, while not disproven,
should for the moment be viewed with an element of caution un-
til confirmation can be provided using bona-fide patient-derived
cells, although it is worth noting that more recent studies are now
beginning to address this point.
Fundamental to our understanding of aberrant TNFR1 sig-
nalling is the compartmentation of the receptor. TNFR1, as with
several cell surface receptors including TNFR6 (also known as
Fas), traffics between the cell surface and Golgi storage pool
[48,49], where TNFR1 predominantly localizes under resting
conditions [5–8]. While the ability of cells to internalize TNF-
bound TNFR1 and trigger apoptosis is well documented [15],
the contribution of TNFR1 cycling dysfunction to inflamma-
tion pathophysiology is less well studied. The importance of this
should not go unstated, however, as for instance there are pro-
found implications for TNFR1 signalling should newly synthes-
ized TNF and recycling TNFR1 meet in the same compartment
of the endosomal system.
Elevated levels of cell surface TNFR1 have been reported in
PBMCs isolated from TRAPS patients carrying a C73R mutation
in TNFR1 in the absence of pro-inflammatory stimuli [50]. As
C73R does not give rise to a TNFR1 shedding defect [51], this
led the authors to speculate that the C73R mutation might in-
stead result in failure to retain the receptor within the Golgi [50],
with the C73R mutation either masking a Golgi retention motif
within this region or in an area of the molecule that is influenced
by mutations in this region. Alternatively the C73R mutation
might instead abolish a Golgi retrieval signal, resulting in fail-
ure to internalize TNFR1 and return it to the Golgi storage pool.
Unfortunately, however, the study in which this data appeared
came from an investigation detailing the cell surface expression
profiles of just three different TRAPS mutations. Moreover, of
these TRAPS mutations only C73R was a fully penetrant dis-
ease mutation. Cell surface localization might therefore also be
evident in other mutations that alter peptide sequence and/or
protein conformation within CRD2. Clearly, more extensive in-
vestigation of Golgi retention/retrieval needs to be undertaken in
cells with other TNFRSF1A mutations before we can confidently
state whether this mechanism of induction of NF-κB activity
is unique to the C73R mutation in TNFRSF1A, or is perhaps
instead a more common mechanism of TNFR1 dysfunction in
TRAPS.
CONSEQUENCES OF TNFR1
TRAFFICKING DYSFUNCTION UPON
CYTOKINE SECRETION
Measurements of serum cytokine levels from a cohort of TRAPS
patients not having a clinical flare at the time of sample collection
revealed elevated levels of IL-6, TNF and the pro-inflammatory
chemokine IL-8 [39,52]. Many patients with TNFR1 mutations
were also found to have elevated CRP levels. Together, these
findings illustrate that even under resting conditions, cells from
TRAPS patients experience ongoing inflammatory activity. In
addition it is also known that the acute-phase inflammatory re-
sponse in TRAPS patients is also associated with increased pro-
duction of pyrogenic cytokines, namely IL-6, IL-1β and TNF,
as well as CRP and serum amyloid A [53]. Increased secre-
tion of pyrogenic cytokines is also observed after infliximab
stimulation of PBMCs isolated from TRAPS patients with the
T50M mutation in TNFRSF1A [47], as well as decreased se-
cretion of the anti-inflammatory cytokine IL-4 [54]. The mech-
anism of TRAPS-associated cytokine release is, however, more
complex than would first appear, as recent work has shown that
different TRAPS mutations stimulate distinct NF-κB family sub-
unit activities. Specifically, mutations resulting in high NF-κB
p65 subunit activity triggered increased IL-8 secretion, whereas
those resulting in high c-Rel activity increased IL-1β and IL-12
secretion [55]. Thus different NF-κB subunits may serve as inde-
pendent inflammatory stimuli, with each NF-κB subunit activity
being dependent on the nature of the specific TNFR1 muta-
tion. However, together these distinct NF-κB subunit actions
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
108 C©The Authors Journal compilation C©2012 Biochemical Society© 2011 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
2
TNFR1-mediated cytokine secretion
are complementary in generating the inflammatory features of
TRAPS.
IL-1β is a pro-inflammatory cytokine that induces the pro-
duction of several cytokines, including itself, TNF, IL-6, IL-8
and IL-12. It also can be induced by acute-phase proteins such
as CRP [56]. Early evidence suggests that anti-IL-1 drugs
such as Anakinra provide encouraging prognoses in patients with
TRAPS, suggesting that IL-1 might also serve to amplify the pro-
inflammatory background in TRAPS patients. Another potential
candidate that might also induce cytokine activation is IL-6, as we
know that CRP is modulated by IL-6 [57] and that IL-6 secretion
is elevated in isolated PBMCs with certain TRAPS mutations in
response to pro-inflammatory stimulation [47,55]. Indeed, recent
preliminary findings indicate that the administration of anti-IL-6
drug tocilizumab could prove a useful tool to successfully attenu-
ate and subsequently prevent acute inflammatory TRAPS attacks,
although the underlying disease pathogenesis still remains [58].
IL-8 also plays an important regulatory role, with monocytes
and fibroblasts producing IL-8, a chemoattractant for neutro-
phils, during inflammation. This chemokine might also have a
role in the dermatological manifestations notable in TRAPS, and
in addition monocytic fasciitis has also been observed in affected
muscles during attacks of TRAPS [3].
Upon binding TNF at the cell surface, two spatially distinct
TNFR1 signalling complexes are formed which have the capacity
to signal either NF-κB activation from the cell surface or apop-
tosis from internalized receptosomes [12–14], thereby indicating
that TNFR1 compartmentalization has an important role in driv-
ing TNF-mediated biological responses [15,16]. Furthermore, it
is known that conformational changes in the extracellular portion
of TNFR1 interfere with receptor internalization and subsequent
activation of apoptotic pathways [59]. In addition, inhibition of
TNFR1 internalization either by deletion of the TNFR1 intern-
alization domain [59] or by infection with an adenovirus [60]
blocked apoptotic signalling complex recruitment, while still al-
lowing recruitment of signalling molecules associated with NF-
κB activation. Thus an internalization defect would likely result
in an accumulation of TNFR1 at the cell surface, thereby leading
to a constitutive activation of the receptor and the subsequent
activation of NF-κB, as has been reported for C73R cells [50].
In addition, the absence of internalization is synonymous with
defective formation of TNFR1 complex II that is required for ac-
tivation of apoptosis. This would also explain the observation that
T50M cells similarly failed to trigger apoptosis following incub-
ation with the anti-TNF mAb (monoclonal antibody), infliximab
[47], or similarly that C43S cells were found to shed normally yet
be insensitive to TNF-induced apoptosis [17] and other cysteine
and threonine mutations showed a modest shedding defect and
yet were also insensitive to TNF-induced apoptosis [46]. In ad-
dition, failure to internalize TNFR1 receptors is also likely to be
further compounded by the activation of anti-apoptotic c-Rel NF-
κB subunits [47]. These pathways are summarized in Figure 2.
Synthesis of cytokines, such as TNF-α, IL-1β, IL-6 and IL-8,
is mediated by NF-κB. NF-κB is also able to function in concert
with other transcription factors, including AP-1 (activator protein
1). For example, NF-κB translocation enhances transcription of
the collagenase-3 gene, also known as MMP13 (matrix metallo-
proteinase 13), in IL-1-stimulated synoviocytes [61]. However,
expression of collagenase gene transcription also depends on the
participation of AP-1, whose transcriptional induction follows a
distinct pathway involving phosphorylation of the MAPK, JNK
and subsequent phosphorylation of c-Jun. Therefore, as AP-1 and
NF-κB are simultaneously activated in IL-1 or TNF-stimulated
PBMC, as well endothelial cells from TRAPS patients, TNFR1
trafficking dysfunction is likely to involve coordinated stimula-
tion of both NF-κB and AP-1.
Additional insight into the complexity of TRAPS biology
came from findings that revealed a regulatory role of IRFs
[IFN (interferon)-regulatory factors] in TNFR1 signalling. The
investigation of signal transduction has typically focused on
direct early events, but analysis of the mechanisms by which
signals are propagated over time and the importance of autocrine
loops in regulating cellular responses has started to gain more
attention [62–65]. It was recently found that in myeloid cells,
TNF initiated a type I IFN-mediated autocrine loop that sustained
the expression of inflammation-related genes such as Cxcl9,
Cxcl10 and Cxcl11 and led to the expression of genes encoding
classic IFN-response molecules, including those known to me-
diate antiviral responses and prime macrophages for enhanced
subsequent responses to cytokines and microbial products [66].
TNF-mediated production of IFN-β and subsequent autocrine
regulation of gene expression was dependent on IRF1 and on
synergy between small amounts of IFN produced and additional
TNF-induced signals, such as activation of NF-κB. These
findings identified a hitherto unknown TNF-activated IRF1-IFN
JAK/STAT (Janus kinase/signal transducer and activator of
transcription) signalling pathway that not only contributes to
the pro-inflammatory functions of TNF, and provided evidence
that induction of IFN-mediated autocrine loops is not limited
to pattern-recognition receptors but also contributes to mac-
rophage response to endogenous inflammatory factors such as
TNF [67].
Defective TNFR1 internalization might also explain some of
the chronic inflammation and flare symptoms observed in TRAPS
patients. Indeed a model in which persistent stimulation with
TNF activates NF-κB and MAPK pathways would lead to rapid
expression of inflammatory genes and to higher expression of
IRF1. As detailed above, this would in turn activate JAK/STAT
signalling that acts in synergy with other TNF-induced signals
to sustain expression of inflammatory chemokines and IFN-β,
inducing slow and delayed accumulation of mRNA molecules
encoded by canonical IFN-response genes, increased expression
of signalling components such as IKK-ε (inhibitor of NF-κB
kinase ε), IRF7 and STAT1 that are known to further amplify the
activation of genes by low concentrations of IFN, and shift the
balance of macrophage responses in an inflammatory direction
[62,68–70]. Thus, TNF-induced gene expression could be sus-
tained and amplified by the sequential induction of IRF1, IFN-β
and STAT1. TNF would thereby activate a ‘feed-forward’ loop
that sustains inflammation but avoids the potential toxicity asso-
ciated with the high IFN production induced by stimulation of
Toll-like receptors.
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Figure 2 Anti-TNF drug infliximab activates NF-κB c-Rel and p65 subunits, and triggers secretion of the pro-inflammatory
cytokines IL-1β, IL-6, IL-8 and IL-12 in PBMCs isolated from TRAPS patients
(1) The mAb anti-TNF drug infliximab triggers pro-inflammatory cytokine secretion due to failure to internalize or shed cell
surface TNFR1, (2) resulting in TNF-stimulated NF-κB activation through the canonical pathway or ligand-independent TNFR1
signalling. This in turn results in nuclear translocation of p65 and c-Rel subunits of NF-κB, c-Rel-mediated reinforcement of
the inhibition of apoptosis, and (3) transcriptional activation of cell survival pathways, increased pro-inflammatory cytokine
secretion and the onset of TRAPS.
CONCLUSIONS
As our understanding of TNFR1 biology continues to grow, so
does the complexity of TNF signalling and its cross-talk with
other signalling mediators. Similarly, the biology underpinning
TNFR1 dysfunction in TRAPS is also far from straightforward,
with multiple models of trafficking dysfunction having been
linked to various respective TNFR mutations. In addition, ligand-
independent signalling adds an extra dimension to the underlying
disease pathophysiology. Despite the existence of these diverse
models of TNFR1 dysfunction, there is, however, one unify-
ing factor common to most of these mechanisms, namely en-
hanced NF-κB activity. Even here, however, the situation is far
from straightforward, as in addition to transcriptional activation
through p65/p50 heterodimers, recent studies indicate a growing
role for c-Rel in inflammatory disease pathogenesis, including
TRAPS [55]. Interestingly, c-Rel is also activated by the anti-
TNF drug infliximab in PBMCs isolated from TRAPS patients
[47], and this has been proposed to be the result of defective
TNFR1 internalization, and/or cell surface activation of TNFR1
that is unable to be shed (Figure 2). Given that there is also
now increasing evidence for additional transcriptional regulation
through MAPK activation of AP-1, no doubt there will be further
bumps in the road ahead as we continue to develop a better under-
standing of TRAPS disease pathophysiology. However, it is only
through more detailed knowledge of TRAPS-associated dysfunc-
tion of TNFR1 biochemistry and cell biology that we can hope
to develop more effective targeted therapeutic treatment options.
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